Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Hemostemix Inc. announced full Bahamas LARTA Board approval, including ethics approval, for a commercial Phase 1 study of VesCell as a treatment for angina, vascular dementia and pain. The release also details a non-brokered private placement of up to $1,000,000 at C$0.05 per unit, with an initial closing of C$380,500, plus a manufacturing update noting CytoImmune test batches of ACP-01 moving into the cleanroom and a decision not to proceed with the CytoImmune bioreactor licence.
Key figures
- Unit price
- C$0.05
- Initial closing gross
- C$380,500
- Warrant exercise price
- C$0.12
- Prior placement proceeds
- $682,250
- Private placement target
- up to $1,000,000
- Units issued initial closing
- 7610000
- Subjects in completed studies
- 318
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.